Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 555-574 , October 2009

Acromegaly

  • Philippe Chanson, MD (Professor and Head)

      Affiliations

    • Corresponding Author InformationCorresponding author. Assistance Publique-Hôpitaux de Paris, Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, 78 rue du Général Leclerc, F-94275 Le Kremlin-Bicêtre, France. Tel.: +33 1 45213705; Fax: +33 1 45212212.
    • ,
  • Sylvie Salenave, MD (Hospital Practitionner)
    • ,
  • Peter Kamenicky, MD, PhD (Associate Professor)
    • ,
  • Laure Cazabat, MD (Associate Professor)
    • ,
  • Jacques Young, MD, PhD (Professor)

References 

  1. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2:29–41
  2. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4769–4775
  3. Schneider HJ, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clinical Endocrinology. 2008;69:432–435
  4. Nabarro JD. Acromegaly. Clinical Endocrinology. 1987;26:481–512
  5. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994;73:233–240
  6. Melmed S. Acromegaly. In:  Melmed S editors. The pituitary. Malden, Mas, USA: Blackwell Science Inc.; 2002;p. 419–454
  7. Nachtigall L, Delgado A, Swearingen B, et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2035–2041
  8. Asa SL, Kovacs KT, Melmed S. Functional anatomy of the hypothalamic pituitary axis. In:  Melmed S editors. The pituitary. 2nd edn.. Malden, Mas, USA: Blackwell Science Inc.; 2002;p. 3–44
  9. Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nature Reviews Cancer. 2004;4:285–295
  10. Beck-Peccoz P, Bassetti M, Spada A, et al. Glycoprotein hormone alpha-subunit response to growth hormone (GH)-releasing hormone in patients with active acromegaly. Evidence for alpha-subunit and GH coexistence in the same tumoral cell. The Journal of Clinical Endocrinology and Metabolism. 1985;61:541–546
  11. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary adenomas. Endocrine Reviews. 1996;17:610–638
  12. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. European Journal of Endocrinology. 2003;148:433–442
  13. Melmed S. Medical progress: acromegaly. The New England Journal of Medicine. 2006;355:2558–2573
  14. Herman V, Fagin J, Gonski R, et al. Clonal origin of pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 1990;71:1427–1430
  15. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987;330:566–568
  16. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocrine Reviews. 2007;28:165–186
  17. Filippella M, Galland F, Kujas M, et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology. 2006;65:536–543
  18. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. The Journal of Clinical Investigation. 2003;112:1603–1618
  19. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nature Reviews Cancer. 2002;2:836–849
  20. Chanson P, Salenave S, Droumaguet C, et al. Rare causes of acromegaly. In:  Wass JA editors. Acromegaly: a handbook of history, current therapy and future prospects. Bristol, UK: Bioscientifica Ltd; 2009;p. 70–98
  21. Chanson P, Salenave S. Acromegaly. Orphanet Journal of Rare Diseases. 2008;3:17
  22. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews. 2004;25:102–152
  23. Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. Journal of Endocrinological Investigation. 2003;26:1242–1247
  24. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. The Journal of Clinical Endocrinology and Metabolism. 2009;94:1509–1517
  25. Molitch ME. Clinical manifestations of acromegaly. Endocrinology and Metabolism Clinics of North America. 1992;21:597–614
  26. Danzig J. Acromegaly. BMJ. 2007;335:824–825
  27. Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2008;93:4649–4655
  28. Miller A, Doll H, David J, et al. Impact of musculoskeletal disease on quality of life in long-standing acromegaly. European Journal of Endocrinology. 2008;158:587–593
  29. Jenkins PJ, Sohaib SA, Akker S, et al. The pathology of median neuropathy in acromegaly. Annals of Internal Medicine. 2000;133:197–201
  30. Tagliafico A, Resmini E, Nizzo R, et al. The pathology of the ulnar nerve in acromegaly. European Journal of Endocrinology. 2008;159:369–373
  31. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of Internal Medicine. 1990;113:921–925
  32. Kamenicky P, Viengchareun S, Blanchard A, et al. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology. 2008;149:3294–3305
  33. Maison P, Demolis P, Young J, et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clinical Endocrinology. 2000;53:445–451
  34. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. The Journal of Clinical Endocrinology and Metabolism. 2000;85:193–199
  35. Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology. 2001;54:189–195
  36. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocrine Reviews. 1994;15:555–573
  37. Clayton RN. Cardiovascular function in acromegaly. Endocrine Reviews. 2003;24:272–277
  38. Gouya H, Vignaux O, Le Roux P, et al. Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. AJR American Journal of Roentgenology. 2008;190:1576–1582
  39. Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. The Journal of Clinical Endocrinology and Metabolism. 2004;89:5308–5313
  40. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. The Journal of Clinical Endocrinology and Metabolism. 2003;88:3196–3201
  41. Pereira AM, van Thiel SW, Lindner JR, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2004;89:71–75
  42. Freda PU, Shen W, Heymsfield SB, et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2334–2343
  43. Katznelson L. Alterations in body composition in acromegaly. Pituitary. 2009;12:136–142
  44. Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. European Journal of Endocrinology. 2004;151:309–315
  45. Attal P, Claes V, Bobin S, et al. Growth hormone excess and sternohyoid muscle mechanics in rats. The European Respiratory Journal, (in press, available on line).
  46. Ip MSM, Tan KCB, Peh WCG, et al. Effect of Sandostatin® LAR® on sleep apneoa in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clinical Endocrinology. 2001;55:477–483
  47. Melmed S. Acromegaly and cancer: not a problem?. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2929–2934
  48. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2935–2941
  49. Renehan AG, O'Connell J, O'Halloran D, et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Hormone and Metabolic Research. 2003;35:712–725
  50. Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a prospective colonoscopic and pathological study in 103 patients. The Journal of Clinical Endocrinology and Metabolism. 1995;80:3223–3226
  51. Trainer PJ, Barth J, Sturgeon C, et al. Consensus statement on the standardisation of GH assays. European Journal of Endocrinology. 2006;155:1–2
  52. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. The Journal of Clinical Endocrinology and Metabolism. 2000;85:526–529
  53. Cazabat L, Souberbielle JC, Chanson P. Dynamic tests for the diagnosis and assesment of treatment efficacy in acromegaly. Pituitary. 2008;11:129–139
  54. Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. The Journal of Clinical Endocrinology and Metabolism. 2002;87:3537–3542
  55. Trainer PJ. Editorial: acromegaly–consensus, what consensus?. The Journal of Clinical Endocrinology and Metabolism. 2002;87:3534–3536
  56. Kovacs K, Lloyd R, Horvath E, et al. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. American Journal of Pathology. 1989;134:345–353
  57. Sakharova AA, Dimaraki EV, Chandler WF, et al. Clinically silent somatotropinomas may be biochemically active. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2117–2121
  58. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. The Journal of Clinical Endocrinology and Metabolism. 2008;93:61–67
  59. Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2004;89:1613–1617
  60. Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4081–4086
  61. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology. 2008;159:89–95
  62. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2004;89:667–674
  63. Chanson P, Maison P. Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?. Nature Clinical Practice in Endocrinology and Metabolism. 2009;5:70–71
  64. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. The Journal of Clinical Endocrinology and Metabolism. 2004;89:5369–5376
  65. Maison P, Chanson P. Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. Nature Clinical Practice in Endocrinology and Metabolism. 2006;2:650–651
  66. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4054–4058
  67. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinology and Metabolism Clinics of North America. 1992;21:669–692
  68. Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3419–3426
  69. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2000;85:4596–4602
  70. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. European Journal of Endocrinology. 2005;152:379–387
  71. Cappabianca P, Cavallo LM, de Divitiis E. Endoscopic endonasal transsphenoidal surgery. Neurosurgery. 2004;55:933–940discussion 940–931
  72. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. [see comments] The Journal of Clinical Endocrinology and Metabolism. 1997;82:3187–3191
  73. Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2476–2482
  74. Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. [In Process Citation] The Journal of Clinical Endocrinology and Metabolism. 2000;85:3779–3785
  75. Brada M, Burchell L, Ashley S, et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. International Journal of Radiation Oncology Biology Physics. 1999;45:693–698
  76. Mahmoud-Ahmed AS, Suh JH, Mayberg MR. Gamma knife radiosurgery in the management of patients with acromegaly: a review. Pituitary. 2001;4:223–230
  77. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. The Journal of Clinical Endocrinology and Metabolism. 2003;88:3105–3112
  78. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4483–4488
  79. Newman CB. Medical therapy for acromegaly. Endocrinology and Metabolism Clinics of North America. 1999;28:171–190
  80. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. The Journal of Clinical Endocrinology and Metabolism. 1998;83:374–378
  81. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. The New England Journal of Medicine. 1996;334:246–254
  82. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995-Acromegaly Study Group. The Journal of Clinical Endocrinology and Metabolism. 1990;71:391–397
  83. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clinical Pharmacokinetics. 1993;25:375–391
  84. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. [see comments] The Journal of Clinical Endocrinology and Metabolism. 1998;83:3034–3040
  85. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs. 1997;53:681–699
  86. Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2005;90:4465–4473
  87. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2779–2786
  88. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clinical Endocrinology. 2000;53:577–586
  89. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2002;87:99–104
  90. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow- release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4554–4563
  91. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. JThe Journal of Clinical Endocrinology and Metabolism. 1997;82:3308–3314
  92. Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a meta- analysis of acromegaly studies. The Journal of Clinical Endocrinology and Metabolism. 2009;
  93. Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews. 2002;23:623–646
  94. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. [see comments] The New England Journal of Medicine. 2000;342:1171–1177
  95. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754–1759
  96. Jimenez C, Burman P, Abs R, et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology. 2008;159:517–523
  97. van der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. The Journal of Clinical Endocrinology and Metabolism. 2001;86:478–481
  98. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology. 2007;156:75–82

PII: S1521-690X(09)00068-2

doi: 10.1016/j.beem.2009.05.010

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 555-574 , October 2009

Article Tools

* Image Usage & Resolution